US2013164811A1PendingUtilityA1

Dna damaging agents in combination with tyrosine kinase inhibitors

66
Assignee: KUFE DONALDPriority: Feb 4, 1994Filed: Jun 26, 2012Published: Jun 27, 2013
Est. expiryFeb 4, 2014(expired)· nominal 20-yr term from priority
Inventors:Donald W. KufeRalph R. Weichselbaum
A61K 41/17A61K 31/7072A61K 31/40A61K 31/7048A61K 31/70A61K 31/704A61N 5/10A61K 41/0023A61K 31/365
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A process of selectively activating the lyn family of Src-like tyrosine kinases in a cell that expresses the lyn gene, the process comprising exposing the cell to an effective dose from a Cesium-137 source. 
     
     
         23 . The process of  claim 22 , wherein the lyn family of Src-like tyrosine kinases comprises p56/p53 lyn . 
     
     
         24 . The process of  claim 22 , wherein the Cesium-137 source has photon energy with a photopeak at 662 keV. 
     
     
         25 . The process of  claim 22 , wherein the dose of Cesium-137 is at least 50 cGy. 
     
     
         26 . The process of  claim 22 , wherein the dose of Cesium-137 is between 50 and 500 cGy. 
     
     
         27 . The process of  claim 22 , wherein the dose of Cesium-137 is 200 cGy. 
     
     
         28 . The process of  claim 22 , wherein the cell is a part of a human subject exposed to Cesium-137 source.

Join the waitlist — get patent alerts

Track US2013164811A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.